Biomarkers in malignant mesothelioma: Diagnostic and prognostic role of soluble mesothelin-related peptide

International Journal of Biological Markers

Volumn 26, Issue 3, 2011, Pages 160-165

  Dipalma, Nicola ^a   Luisi, Vito ^a   Di Serio, Francesca ^a   Fontana, Antonietta ^a   Maggiolini, Piera ^a   Licchelli, Brunella ^a   Mera, Ernesto ^a   Bisceglia, Lucia ^b   Galise, Ida ^b   Loizzi, Michele ^a   Pizzigallo, Maria Annunziata ^a   Molinini, Raffaele ^a   Vimercati, Luigi ^c  

^a POLICLINICO   (Italy)

^b Environmental Protection Agency (ARPA Puglia)   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Biological markers; Mesothelin; Mesothelioma

Indexed keywords

ASBESTOS; PROTEIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESOTHELIN; PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASBESTOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; METASTASIS; OCCUPATIONAL EXPOSURE; PLEURA CANCER; PLEURA PLAQUE; PROGNOSIS; PROTEIN DETERMINATION; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PEPTIDES; PROGNOSIS;

EID: 80053344031     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8614     Document Type: Article

References (21)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-72.
2. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009; 136: 888-96.
3. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94.
4. Robinson BW, Creaney J, Lake R, et al.Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6.
5. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-81.
6. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-60.
7. Nesti M, Adamoli S, Ammirabile F, et al. Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali; II Edizione. ISPESL 2004.
8. American Thoracic Society. Diagnosis and initial management of non-malignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691-715.
9. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8.
10. Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007; 45: 634-8.
11. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
12. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999; 25: 25-32.
13. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med 1999; 29: 765-9.
14. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001; 92: 1224-30.
15. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28: 3316-22.
16. Cristaudo A, Foddis R, Bonotti A, et al. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels. Int J Biol Markers 2011; 26: 117-23.
17. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelinrelated protein in an asbestos-exposed population: the Dust Diseases Board Cohort study. J Respir Crit Care Med 2008; 178: 832-7.
18. Cristaudo A, Foddis R, Buselli R, et al. Medical surveillance of workers previously exposed to asbestos. Med Lav 2006; 97: 475-81.
19. Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor- associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008;17: 163-70.
20. Creaney J, Olsen NJ, Brims F, et al. Serum mesothelin for early detection of the asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2238-46.
21. Shah N, Williams A. Surviving the asbestos epidemic. Insur Digest 2001; 15: 14-8.